Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
KPTI Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Karyopharm Therapeutics Inc.NASDAQ: KPTI
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $1.36M rose 4.3% year over year, behind the +9.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.
Context
- Cost of revenue amounted to 4.1% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +4.3% toward the trailing-twelve-month pace of +9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 5.95M USD
- Year-over-year change
- -1.0%
- 4-year CAGR
- +15.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.95M | -1.0% |
| FY2024 | 2024-12-31 | 6.01M | +21.5% |
| FY2023 | 2023-12-31 | 4.94M | -5.2% |
| FY2022 | 2022-12-31 | 5.21M | +53.2% |
| FY2021 | 2021-12-31 | 3.4M | — |
Cost of Revenue vs competitors
How KPTI compares with its peers on the latest reported figures
- KPTI's LTM Mar 2026 cost of revenue of $6.01M is the highest of the 4 companies compared; the peer median is $108K.
- Its year-over-year change of +9.4% is the highest of 2, against a peer median of -69.5%.
- Cost of revenue amounts to 4.0% of revenue for KPTI, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.01M | +9.4% | +4.5% | 4.0% | |
| LTM Mar 2026 | $1.85M | -69.5% | — | 20.6% | |
| LTM Mar 2026 | $108K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding KPTI) | $108K | -69.5% | — | 20.6% | |
Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M |
| Cost of Revenue | 3.4M | 5.21M | 4.94M | 6.01M | 5.95M |
| Gross Profit | 206.42M | 151.86M | 141.09M | 139.23M | 140.12M |
| Gross Margin | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% |
| Research & Development | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M |
| Selling, General & Admin | 143.85M | 145.4M | 131.88M | 115.44M | 105.21M |
| Operating Expenses | 304.69M | 294.06M | 270.63M | 258.67M | 230.83M |
| Depreciation & Amortization | 789K | 621K | 530K | 340K | 296K |
| EBITDA | (96.99M) | (139.31M) | (118.42M) | (38.6M) | (149.85M) |
| EBITDA Margin | -46.2% | -88.7% | -81.1% | -26.6% | -102.6% |
| Operating Income | (98.27M) | (142.2M) | (129.54M) | (119.44M) | (90.71M) |
| Operating Margin | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Interest Income | 582K | 2.36M | 10.94M | 7.4M | 2.77M |
| Interest Expense | 26.05M | 25M | 23.82M | 37.42M | 45.85M |
| Other Income / Expenses | (25.55M) | (22.72M) | (13.24M) | 43.08M | (105.29M) |
| Income Before Tax | (123.82M) | (164.92M) | (142.78M) | (76.37M) | (196M) |
| Pre-Tax Margin | -59.0% | -105.0% | -97.8% | -52.6% | -134.2% |
| Income Tax Expense | 268K | 369K | 323K | 57K | 43K |
| Net Income | (124.09M) | (165.29M) | (143.1M) | (76.42M) | (196.04M) |
| Net Margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (Basic) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| EPS (Diluted) | (24.75) | (30.28) | (18.79) | (9.41) | (17.93) |
| Weighted Avg Shares | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M |
| Weighted Avg Shares (Diluted) | 5.01M | 5.46M | 7.61M | 8.12M | 10.94M |
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
Intrinsic Alpha fair value
Locked
Current Price
$7.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.